Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 23%
Buy 8%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health Inc. is experiencing robust subscriber growth, particularly in the weight-loss sector, with a reported 70% year-over-year increase in subscribers in Q4, which bodes well for sequential revenue growth into subsequent quarters. The company's diversification into various healthcare specialties has mitigated concentration risk, ensuring resilience in its revenue streams, even as it capitalizes on growth in the GLP-1 market. Additionally, strategic partnerships and new product offerings position Hims & Hers to leverage future sales in emerging weight-loss medications, further enhancing its positive growth outlook through 2026.

Bears say

Hims & Hers Health Inc. faces a negative outlook primarily due to significantly slowing revenue growth, as indicated by disappointing 4Q:25 earnings and weak revenue guidance for 1Q:26. The company's full-year 2026 revenue estimate has been revised downward, projecting between $2.7 billion and $2.9 billion, which is lower than previous expectations and highlights concerns about sustained growth. Additionally, increased legal and regulatory risks contribute to the negative sentiment surrounding the stock, as the latest financial metrics indicate a decline in both revenue and EBITDA forecasts for 2027.

HIMS has been analyzed by 13 analysts, with a consensus rating of Hold. 23% of analysts recommend a Strong Buy, 8% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Hold based on their latest research and market trends.

According to 13 analysts, HIMS has a Hold consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.